Clarient says it has licensed technology for testing for cancer from Minerva Biotechnologies for an undisclosed sum. Clarient said the test it acquired is an improved diagnostic for cancer capable of identifying the MUC1 protein, considered a biomaker for various cancers. Clarient said the test requires at least a year of development before its potential could be determined. (Click here for more)
“Clarient Licenses Potential Cancer Testing Technology From Minerva Biotechnologies” – Minneapolis Star Tribune (AP) (11/30/09)
Hot Off the Presses: Medical Device Market 2009: Interventional Cardiology - This 86-page Special Report from IN VIVO identifies the most important trends in cardiology devices in recent years, teases out the critical decisions that drove those developments, and takes you behind the scenes and into the minds of the architects of these new technologies and business strategies. Find out more...

